Getinge unit Maquet loses Abiomed heart pump patent trial in US jury verdict

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Getinge unit Maquet Cardiovascular lost a US jury trial in Massachusetts in a patent dispute with Abiomed over intravascular heart-pump technology.
  • Jury found Abiomed did not infringe Maquet patents tied to Impella percutaneous ventricular assist devices; Maquet is weighing next steps.
  • Verdict covers one of two cases between the companies; the second patent litigation remains ongoing.
  • Getinge flagged no negative financial or operational impact from the verdict.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getinge AB published the original content used to generate this news brief via PR Newswire (Ref. ID: HS70532) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.